Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries

All invasive, primary, malignant neoplasms except non-melanoma skin cancer were eligible for inclusion.

Data consists of both observed and predicted 5-year relative survival.

Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

For some European countries data is not available for one or both sexes.

95% LCL and 95% UCL are the 95% lower and upper confidence limits around the five-year relative survival.

Source: cruk.org/cancerstats

You are welcome to reuse this Cancer Research UK statistics content for your own work.

Credit us as authors by referencing Cancer Research UK as the primary source.

Suggested style: Cancer Research UK, full URL of the page, Accessed [month] [year].

| Sex | Bulgaria | Latvia | Poland | Lithuania | Scotland | Wales | Ireland | England | Slovakia | Northern Ireland | Portugal | France | European Average | Czech Republic | Germany | Spain | Switzerland | Estonia | Denmark | Croatia | The Netherlands | Austria | Belgium | Sweden | Finland | Italy | Slovenia | Ireland | Norway | Malta |
|-----|----------|--------|--------|-----------|----------|-------|---------|---------|---------|---------------|---------|--------|---------------|---------------|---------|-------|-------------|---------|---------|---------|----------|--------|---------|----------|--------|-------|
| Women | 50.08 | 51.02 | 53.63 | 58.04 | 57.89 | 58.10 | 58.87 | 58.59 | 60.37 | 61.13 | 61.26 | 61.36 | 62.36 | 62.07 | 63.53 | 63.91 | 63.91 | 64.16 | 64.27 | 65.38 | 65.83 | 66.14 | 66.46 | 66.77 | 67.27 | 67.51 | 68.26 | 69.18 | 69.59 | 71.01 |
| 5-Year Relative Survival (%) | 50.08 | 51.02 | 53.63 | 58.04 | 57.89 | 58.10 | 58.87 | 58.59 | 60.37 | 61.13 | 61.26 | 61.36 | 62.36 | 62.07 | 63.53 | 63.91 | 63.91 | 64.16 | 64.27 | 65.38 | 65.83 | 66.14 | 66.46 | 66.77 | 67.27 | 67.51 | 68.26 | 69.18 | 69.59 | 71.01 |
| 95% LCL | 49.60 | 48.15 | 51.76 | 54.08 | 53.45 | 50.00 | 55.75 | 58.72 | 58.33 | 56.34 | 59.48 | 58.04 | 61.80 | 61.05 | 62.33 | 61.30 | 59.69 | 60.85 | 62.33 | 62.87 | 64.20 | 64.37 | 64.45 | 64.87 | 64.25 | 66.19 | 65.15 | 61.39 | 68.56 |
| 95% UCL | 52.39 | 54.05 | 55.57 | 58.06 | 60.44 | 61.38 | 62.16 | 60.47 | 62.47 | 60.32 | 63.11 | 62.03 | 64.31 | 64.75 | 66.73 | 68.43 | 67.70 | 68.71 | 67.38 | 67.50 | 67.95 | 68.60 | 69.73 | 70.44 | 68.86 | 71.33 | 70.89 | 73.58 |

Note: Cervical, primary, malignant neoplasms, female-incident cases eligible for inclusion.

Data provided for Europe as a whole was not available for this specific year. Data provided for the period approach was used to predict 5-year cohort survival.

For 2005, 2006 and 2007, data are not available for some limited countries.

Women are referenced to remove data for 2005, 2006 and 2007, but limited data are available and some countries are not represented.

Cancer Research UK, full URL of the page, Accessed [month] [year].

You are welcome to reuse this Cancer Research UK statistics content for your own work.

Credit us as authors by referencing Cancer Research UK as the primary source.

Suggested style: Cancer Research UK, full URL of the page, Accessed [month] [year].